BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy

• Published in: Breast cancer research and treatment Vol. 181; no. 2; pp. 323 - 329
• Main Authors: Kawachi, Asuka, Yamashita, Satoshi, Okochi-Takada, Eriko, Hirakawa, Akihiro, Tsuda, Hitoshi, Shimomura, Akihiko, Kojima, Yuki, Yonemori, Kan, Fujiwara, Yasuhiro, Kinoshita, Takayuki, Ushijima, Toshikazu, Tamura, Kenji
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2020; Springer; Springer Nature B.V
• Subjects: Analysis; Biopsy; Bisulfite; BRCA1 protein; BRCA2 protein; Breast cancer; Cancer; Cancer patients; Cancer research; Carboplatin; Care and treatment; Combination therapy; Disease control; DNA methylation; DNA sequencing; Gene mutations; Genetic aspects; Medical colleges; Medicine; Medicine & Public Health; Methylation; Mutation; Oncology; Patients; Poly(ADP-ribose) polymerase; Preclinical Study; Sulfites; DNA methylation; PARP inhibitor; Triple-negative breast cancer; RAD51C; BRCA1

Background A PARP inhibitor is effective in breast cancer patients with BRCA1/2 germline mutations, and in cell lines with BRCA1 promoter methylation. However, its efficacy in breast cancer patients with BRCA1 promoter methylation is still unknown. Methods Biopsy samples were obtained from 32 triple...